Clinical Scorecard: Radiogenomic Assessment Using CT Imaging to Identify ICAM1 and RAET1E as Indicators of NK Cell Cytotoxicity in Clear Cell Renal Cell Carcinoma
At a Glance
Category
Detail
Condition
Clear Cell Renal Cell Carcinoma (ccRCC)
Key Mechanisms
NK cell-mediated cytotoxicity pathways linked to imaging features
Target Population
Patients with histologically confirmed ccRCC
Care Setting
Preoperative assessment using CT imaging
Key Highlights
Development of a noninvasive CT-based radiogenomic framework
Identification of ICAM1 and RAET1E as biomarkers related to NK cell cytotoxicity
Significant association of biomarkers with tumor stage and survival outcomes
External validation achieved predictive accuracies of 76.92% for ICAM1 and 73.08% for RAET1E
835 imaging-associated genes enriched in immune-related pathways identified
Guideline-Based Recommendations
Diagnosis
Utilize preoperative contrast-enhanced CT images for assessment
Management
Consider radiogenomic analysis for noninvasive immune characterization
Monitoring & Follow-up
Monitor expression levels of ICAM1 and RAET1E as indicators of tumor progression
Risks
Higher ICAM1 and lower RAET1E expression associated with advanced tumor stage and unfavorable survival outcomes
Patient & Prescribing Data
143 patients with ccRCC and 538 TCGA-KIRC tumor samples
Radiogenomic features may inform treatment strategies based on immune microenvironment
Clinical Best Practices
Employ L1-penalized support vector machine models for biomarker estimation
Validate findings with immunohistochemistry and external datasets
Integrate radiomic features into clinical decision-making processes
